Assembly Biosciences (NASDAQ: ASMB) — Perfil da empresa, notícias e dados financeiros
Assembly Biosciences develops innovative therapies primarily targeting viral infections and liver diseases.
Assembly Biosciences
Assembly Biosciences (NASDAQ:ASMB) is a biotechnology company focused on developing innovative treatments for diseases with significant unmet needs, primarily targeting viral infections and liver diseases. The company is known for its cutting-edge research in hepatitis B virus (HBV) cure and microbiome therapeutics, aiming to bring novel solutions to patients worldwide. Assembly Biosciences' projects include advanced clinical trials for its leading HBV candidates and exploratory research into the therapeutic potential of microbiome-based treatments. The company's objective is to leverage its expertise in virology and biotherapeutics to create and deliver groundbreaking treatments that can improve the lives of patients suffering from chronic infections and related diseases.
Resumo
Operações
Produtos e/ou serviços de Assembly Biosciences
- Development of novel hepatitis B virus (HBV) core inhibitors aimed at achieving a functional cure for patients.
- Research on microbiome therapies targeting interactions between the human microbiome and various diseases.
- Pipeline of small molecule therapies designed to modulate the gut microbiota for treating conditions like inflammatory bowel disease.
- Collaboration with partners for the advancement of antiviral compounds targeting chronic HBV infection.
- Investigation into the mechanism of action of core protein allosteric modifiers (CpAMs) for potential therapeutic applications.
- Efforts in discovering and developing new class of oral therapeutics focused on viral diseases and disorders associated with the microbiome.
equipe executiva do Assembly Biosciences
- Jason A. OkazakiCEO, President & Director
- William E. Delaney IVChief Scientific Officer
- Anuj GaggarChief Medical Officer
- Jeanette M. BjorkquistPrincipal Financial Officer, Executive Director of Accounting & Treasury
- Shannon RyanSenior Vice President of Investor Relations, Corporate Affairs & Alliance Management
- Jennifer A. TroiaChief Human Resources Officer
- Nicole S. WhiteChief Manufacturing Officer
- Katie KitrinosSenior VP of Preclinical Research & Development
- Thomas E. RollinsExecutive Officer
- Amy FigueroaInvestor Relations Consultant
Últimas notícias sobre a Assembly Biosciences
Principais indicadores financeiros
Resultados divulgados pela Assembly Biosciences, em USD.
- Cap. de mercado
- 413,3 mi
- Receita (TTM)
- 74,8 mi
- P/L
- 19.5
- LPA (diluído, TTM)
- 1.0
- Dividend yield
- —
- Margem de lucro
- -0.1%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 72,3 mi | -12,1 mi | -6,1 mi | |
| 28,5 mi | -45,4 mi | -40,2 mi | |
| 7,2 mi | -64,6 mi | -61,2 mi | |
| 0 | -94,1 mi | -92,1 mi |